Biogen Inc.

WBAG:BIIB Stock Report

Market Cap: €22.1b

Biogen Valuation

Is BIIB undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BIIB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: BIIB (€152.5) is trading below our estimate of fair value (€728.91)

Significantly Below Fair Value: BIIB is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BIIB?

Key metric: As BIIB is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for BIIB. This is calculated by dividing BIIB's market cap by their current earnings.
What is BIIB's PE Ratio?
PE Ratio14.2x
EarningsUS$1.62b
Market CapUS$23.01b

Price to Earnings Ratio vs Peers

How does BIIB's PE Ratio compare to its peers?

The above table shows the PE ratio for BIIB vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average76.2x
A068270 Celltrion
191.2x73.6%₩35.8t
UTHR United Therapeutics
15x8.1%US$16.6b
HZNP Horizon Therapeutics
60.8x16.4%US$26.6b
BMRN BioMarin Pharmaceutical
38x27.3%US$12.2b
BIIB Biogen
14.2x12.4%€23.0b

Price-To-Earnings vs Peers: BIIB is good value based on its Price-To-Earnings Ratio (14.2x) compared to the peer average (81.4x).

Price to Earnings Ratio vs Industry

How does BIIB's PE Ratio compare vs other companies in the European Biotechs Industry?

5 CompaniesPrice / EarningsEstimated GrowthMarket Cap
BIIB 14.2xIndustry Avg. 27.0xNo. of Companies5PE020406080100+
5 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: BIIB is good value based on its Price-To-Earnings Ratio (14.2x) compared to the European Biotechs industry average (27x).

Price to Earnings Ratio vs Fair Ratio

What is BIIB's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BIIB PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio14.2x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate BIIB's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst BIIB forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€152.50
€237.55
+55.8%
18.8%€322.78€169.88n/a29
Nov ’25€160.95
€235.96
+46.6%
17.1%€315.60€166.10n/a29
Oct ’25€174.05
€244.09
+40.2%
13.7%€308.96€171.65n/a30
Sep ’25€183.65
€248.40
+35.3%
13.0%€313.00€173.89n/a30
Aug ’25€193.55
€258.01
+33.3%
13.6%€324.35€185.34n/a30
Jul ’25€216.70
€264.21
+21.9%
14.4%€326.59€186.62n/a30
Jun ’25€206.90
€263.68
+27.4%
14.2%€324.07€185.18n/a29
May ’25€203.00
€267.67
+31.9%
13.4%€327.36€187.06n/a31
Apr ’25€199.10
€277.66
+39.5%
12.7%€369.64€212.54n/a30
Mar ’25€202.80
€277.66
+36.9%
12.7%€369.64€212.54n/a30
Feb ’25€226.60
€288.99
+27.5%
11.1%€374.86€226.21n/a30
Jan ’25€235.40
€283.85
+20.6%
10.2%€357.75€217.01n/a31
Dec ’24€214.20
€297.94
+39.1%
11.1%€368.74€223.68n/a29
Nov ’24€225.00
€307.22
+36.5%
9.2%€378.88€251.96€160.9529
Oct ’24€244.40
€305.31
+24.9%
10.5%€406.44€250.76€174.0529
Sep ’24€248.20
€299.39
+20.6%
10.2%€400.47€247.08€183.6528
Aug ’24€245.40
€304.84
+24.2%
9.7%€396.50€250.99€193.5528
Jul ’24€260.20
€308.15
+18.4%
8.5%€364.65€240.96€216.7027
Jun ’24€283.40
€310.66
+9.6%
8.4%€369.90€244.43€206.9027
May ’24€272.80
€300.32
+10.1%
8.8%€362.78€239.72€203.0027
Apr ’24€256.00
€303.83
+18.7%
9.7%€365.53€234.58€199.1026
Mar ’24€254.95
€304.54
+19.4%
9.6%€366.74€235.35€202.8026
Feb ’24€264.10
€298.41
+13.0%
10.1%€370.60€229.55€226.6026
Jan ’24€257.15
€302.21
+17.5%
8.9%€349.06€233.02€235.4026
Dec ’23€290.30
€303.42
+4.5%
9.3%€351.50€234.65€214.2026
Nov ’23€285.85
€308.67
+8.0%
12.0%€374.59€220.70€225.0026

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Almirall

€1.8b

A biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa.

ALM

€8.40

7D

-0.5%

1Y

0%

Teva Pharmaceutical Industries

US$19.4b

Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.

TEVA

US$16.30

7D

4.2%

1Y

85.6%

Bayer

€19.5b

Operates as a life science company worldwide.

BAYN

€19.77

7D

-3.7%

1Y

-39.4%